CABERGOLINE | A076310 | STRIDES PHARMA INTERNATIONAL AG
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Public Citizen Health Research Group FDA-2016-P-1874 · 7 docket documents Public Citizen, a consumer advocacy organization, filed this petition on June 29, 2016, requesting that the FDA immediately add a boxed warning to product labeling for all dopamine agonist drugs currently approved in the U.S. (apomorphine, bromocriptine, cabergoline, pramipexole, ropinirole, and rot | Other | 2016-07-01 | Denied | Public Citizen Health Research Group |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$1.45
per ea
Lowest NADAC/Unit
$1.45
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 70512086008CABERGOLINE 0.5 MG TABLET | $1.45 | EA | Generic | — | 2026-06-17 |
| 23155082373CABERGOLINE 0.5 MG TABLET | $1.45 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.